Avidity Partners Management LP Regeneron Pharmaceuticals, Inc. Transaction History

Avidity Partners Management LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$883.2 - $1071.19 $17.7 Million - $21.4 Million	-20,000 Reduced 29.41%	48,000 $50.4 Million
Q4 2023 Feb 14, 2024	BUY	$775.18 - $881.7 $7.75 Million - $8.82 Million	10,000 Added 17.24%	68,000 $59.7 Million
Q3 2023 Nov 14, 2023	BUY	$692.45 - $844.37 $23 Million - $28 Million	33,200 Added 133.87%	58,000 $47.7 Million
Q2 2023 Aug 14, 2023	SELL	$700.03 - $830.35 $66 Million - $78.3 Million	-94,300 Reduced 79.18%	24,800 $17.8 Million
Q1 2023 May 15, 2023	BUY	$680.49 - $826.97 $81 Million - $98.5 Million	119,100 New	119,100 $97.9 Million
Q4 2021 Feb 14, 2022	SELL	$543.48 - $670.97 $82.8 Million - $102 Million	-152,300 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$574.03 - $680.96 $87.4 Million - $104 Million	152,300 New	152,300 $92.2 Million
Q3 2020 Nov 16, 2020	SELL	$544.75 - $658.21 $72 Million - $86.9 Million	-132,100 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$493.32 - $643.92 $40.5 Million - $52.9 Million	82,100 Added 164.2%	132,100 $82.4 Million
Q1 2020 Jun 17, 2020	BUY	$336.18 - $494.43 $16.8 Million - $24.7 Million	50,000 New	50,000 $24.4 Million

1,529

84.1M

1.22M

1.51M

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $81.1B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

Get notified when there are updates to the investment portfolio of Avidity Partners Management LP, based on Form 13F filings with the SEC.

Stay updated on Avidity Partners Management LP with notifications on news.